<\/p>\n
<\/p>\n
<\/p>\n
Dextech Medical AB’s shareholders are welcome to participate in the Annual General Meeting that will be held
\nMonday 2 November 2026 at 10.00 a.m. in IVA’s Conference Centre, Kungl. The Royal Swedish Academy of Engineering Sciences, Grev Turegatan 16, Stockholm.
\nAdmission to the Annual General Meeting will begin at 9.30 a.m.<\/p>\n
<\/p>\n
Subject to availability and that the meeting so resolves, non-shareholders are also welcome to participate in the meeting without voting rights.<\/p>\n
<\/p>\n
Registration and registration<\/em><\/p>\n <\/p>\n Shareholders who wish to participate in the Annual General Meeting must:<\/p>\n <\/p>\n <\/p>\n <\/p>\n The notification shall state the full name, personal identity number or corporate registration number, shareholding, address, daytime telephone number and, where applicable, information about the deputy or assistant (maximum 2). The notification shall be accompanied, where applicable, by powers of attorney, registration certificate and other authorization documents.<\/p>\n <\/p>\n The Annual General Meeting will be held in Swedish.<\/p>\n \u00a0<\/em><\/p>\n Nominee-registered shares<\/em><\/p>\n A nominee whose shares are registered in the name of a nominee must, in order to be entitled to participate in the meeting, have the shares registered in their own name through the nominee, so that they are registered in the share register maintained by Euroclear Sweden AB as of the record date on Friday 23 October 2026. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register the shares in their own name must, in accordance with the respective nominee’s procedures, request that the nominee makes such voting rights registration. Voting rights registration that has been requested by shareholders in such time that the registration has been made by the relevant nominee no later than Friday 23 October 2026 will be taken into account in the preparation of the share register.<\/p>\n <\/p>\n Agents, etc.<\/em><\/p>\n If a shareholder is to be represented by a proxy, the proxy must have a written, dated and signed power of attorney for the meeting signed by the shareholder. The power of attorney may not be older than one year, unless a longer period of validity (but not more than five years) has been stated on the power of attorney. If the power of attorney has been issued by a legal entity, the proxy must also bring the current certificate of registration or equivalent authorization documents for the legal entity. To facilitate entry, a copy of the power of attorney and other authorization documents should be attached to the notification of attendance at the meeting. Proxy forms are available on the company’s website www.dextechmedical.com<\/a> and are sent by mail to shareholders who contact the company and state their address.<\/p>\n <\/p>\n Agenda<\/em><\/p>\n <\/p>\n Proposals for resolutions in brief<\/u><\/em><\/p>\n Determination of the number of members of the Board of Directors and deputy members of the Board of Directors (item 12)<\/em><\/p>\n According to the Articles of Association, the Board of Directors shall consist of a minimum of three and a maximum of seven members with a maximum of two deputies. Shareholders representing just over 60% of the total number of shares in the company have proposed that the number of Board members shall be five members and that no deputies be elected.<\/p>\n <\/p>\n Determination of fees (item 13)<\/em><\/p>\n Shareholders representing more than 60% of the total number of shares in the company have proposed that no fees shall be paid to the Board of Directors and that fees to the auditor shall be paid in accordance with approved invoices.<\/p>\n \u00a0<\/em><\/p>\n Election of the Board of Directors (item 14)<\/em><\/p>\n Shareholders representing more than 60% of the total number of shares in the company have proposed that the following persons be elected as members of the Board of Directors:<\/p>\n Re-election of Andreas Segerros, Peter Benson, Per-Olof Asplund, Rolf Eriksson and Svante Wadman, with Andreas Segerros as Chairman.<\/p>\n <\/p>\n Election of auditor (item 15)<\/em><\/p>\n Shareholders representing more than 60% of the total number of shares in the company have proposed the election of Azets Revision & R\u00e5dgivning AB as auditor.<\/p>\n <\/p>\n <\/p>\n The Board’s proposal<\/em><\/p>\n Appropriation of the Company’s result (item 10)<\/em><\/p>\n The funds at the disposal of the Annual General Meeting consist of profit for the year of SEK -6,459,132, the Company’s share premium reserve of SEK 105,195,317 and the Company’s retained profit of SEK -91,100,924, totalling SEK 7,635,261.<\/p>\n The Board of Directors proposes that the funds at the disposal of the Annual General Meeting of SEK 7,635,261 be carried forward.<\/p>\n <\/p>\n Shares and votes<\/u><\/em><\/p>\n There are a total of 18,485,857 shares and an equal number of votes in the company.<\/p>\n <\/p>\n Documents<\/u><\/em><\/p>\n The Annual Report and the Auditor’s Report are available on the company’s website www.dextechmedical.com<\/a>.<\/p>\n <\/p>\n __________________________<\/p>\n \n Stockholm, October 2026<\/strong><\/p>\n \u00a0<\/strong><\/p>\n THE BOARD OF DIRECTORS<\/strong><\/p>\n\n
\n
\n